ArticleJournal of neurology2026
Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSymptoms of Alzheimer's disease can emerge years before diagnosis, but detailed temporal mapping of morbidity and medication use in the prodromal period is lacking.
methodsWe conducted a nationwide retrospective, incidence density-matched nested case-control study including individuals diagnosed with late-onset Alzheimer's disease in Danish memory clinics from 2016 to 2022 and cognitively healthy matched controls. Exposures were primary and secondary discharge diagnoses from hospital contacts, and redeemed prescriptions.
resultsA total of 19,102 patients and 57,306 matched controls were included. At 10 years before diagnosis, individuals who later developed late-onset Alzheimer's disease had more mental health and behavioral diagnoses and increased use of psychopharmaceuticals, as well as more injuries and hospital contacts for non-specific symptoms. During the five years and one-year preceding diagnosis, morbidity increased across multiple diagnostic categories, while most medication categories decreased.
conclusionOur findings suggest that prodromal late-onset Alzheimer's disease is characterized by gradual accumulation of morbidity, with injuries and neuropsychiatric symptoms as the most persistent. This knowledge can guide future hypothesis-driven studies towards better characterization of the prodromal phase that may improve early detection, reduce the burden of unexplained symptoms experienced by patients and their caregivers, and support clinicians facing diagnostic uncertainty.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.